Balance Labs, Inc. 8-K

What Happened
Balance Labs, Inc. (BLNC) filed an 8‑K (Item 5.02) reporting that on February 6, 2026 the Board appointed Alexander Farkas as President and Chief Operating Officer, effective February 9, 2026. The filing describes Mr. Farkas’s background in EV charging, military engineering, early‑stage investing and digital assets, and notes he is the son of Balance Labs’s Chairman, Michael Farkas. The company and Mr. Farkas executed an offer letter (filed as Exhibit 10.1) setting out the material terms of his employment.

Key Details

• Annual base salary: $120,000.
• Bonus: target of 65% of base salary for meeting annual KPIs; potential bonus up to 125% of base salary; Mr. Farkas may elect to receive bonus in common stock.
• Term: initial two‑year term (effective Feb 9, 2026) that automatically renews for successive two‑year terms unless the company gives ≥30 days’ written notice.
• Termination/benefits: for Cause termination pays only compensation due through termination date; if terminated Without Cause by the company or Mr. Farkas leaves for Good Reason, the company will (i) continue base salary for 3 months and (ii) provide COBRA benefits until the earlier of 3 months or eligibility for other employer benefits. The offer letter includes standard restrictive covenants, including non‑competition obligations.

Why It Matters
This filing documents a senior leadership appointment and the specific economics and protections of the role, which investors can use to assess management continuity and compensation structure. The appointment is a related‑party disclosure (Mr. Farkas is the chairman’s son), which investors typically watch for corporate governance implications. The compensation package is modest in base salary with incentive pay tied to KPIs and the option to take bonuses in stock, which could affect future equity dilution and alignment with shareholder interests. The limited severance terms clarify the company’s payout obligations on termination.